Table 1.
Summary table of the effect of bDMARD and tsDMARDs on spine, hip and hand BMD and on erosion repair
| Spine BMD | Hip BMD | Hand BMD | Erosion repair* | ||||
|---|---|---|---|---|---|---|---|
| Ref | Ref | Ref | |||||
| TNFi | +/-- | +/- | [51] [57] [58] [47] | +/-- | [51] [48, 59] | + | [52] |
| Rituximab | +/- | +/-- | [60, 61] | × | x | ||
| Abatacept | +/- | ++/- | [57] [62] | × | + | [63] | |
| IL6i | +/- | ++/- | [64–66] | × | ++ | [67, 68] | |
| JAKi | +/- | +/- | [69] | × | ?+ | [70] |
TNFi tumour necrosis factor inhibitors, IL6i interleukin 6 inhibitors, JAKi janus kinase inhibitors; BMD bone mineral density;
*Erosion repair-assessed by HR-pQCT or MRI, × no data available,±stable, ±—more studies demonstrating BMD loss than gain,+ ± most studies demonstrating BMD stabilisation or gain, +evidence of erosion repair, + + evidence of erosion repair which is superior to other bDMARDs, ? +preliminary data from a small sample size only, Further detailed table on the impact of bDMARDs on bone mass and bone turnover markers is published by Zerbini et al. [47]